Find the CANCER BUZZ podcast on Apple Podcasts, Spotify, or wherever you get your podcasts!
Relapsed/refractory follicular lymphoma (R/R FL) is challenging to treat, requiring thoughtful clinical decision-making during treatment selection and sequencing. In this episode, CANCER BUZZ speaks with Benjamin Heyman, MD, hematologist and clinical associate professor at City of Hope, about the importance of individualized care, shared decision-making, clinical trial referrals, and multidisciplinary collaboration. CANCER BUZZ also speaks with Laurie Adami, patient advocate with R/R FL, about her real-world experience with multiple lines of therapy, clinical trials, and patient advocacy.
“There are lots of options available, which is really great for patients, so you get to have a good conversation with patients about what they value.” - Benjamin Heyman, MD
“The medications you receive in clinical trials may not be the standard of care today, but it may be the standard of care 5 years from now.” - Benjamin Heyman, MD
“Patient advocacy organizations have patients that can talk to you. They know what you’re talking about. They’re on the road ahead of you.” - Laurie Adami
Guests:
Benjamin Heyman, MD
Hematologist
Clinical Associate Professor
City of Hope
San Diego, CA
Laurie Adami
R/R FL Patient Advocate
Los Angeles, LA
Received care at UCLA Lymphoma Program
Additional Reading/Resources
This podcast is made possible with support from BeOne Medicines and Incyte and in collaboration with The Leukemia & Lymphoma Society, now Blood Cancer United, and the Lymphoma Research Foundation.
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Cancer Care Centers.
June 30, 2026
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
